Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference

* Reuters is not responsible for the content in this press release.

Tue Jun 16, 2009 8:00am EDT 

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Sunesis
Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on
the development and commercialization of new oncology therapeutics for the
treatment of solid and hematologic cancers, today announced that Daniel
Swisher, Chief Executive Officer of Sunesis, will be presenting at the
Jefferies 3rd Annual Healthcare Conference at 10:45 a.m. Eastern Time in New
York on June 17, 2009.

The live webcast of this presentation will be available on the Sunesis website
at http://ir.sunesis.com. A replay of the webcast will be archived on the
"Calendar of Events" page in the Investors and Media section of the Sunesis
website for two weeks.

About Sunesis Pharmaceuticals 
Sunesis is a biopharmaceutical company focused on the development and
commercialization of new oncology therapeutics for the treatment of solid and
hematologic cancers. Sunesis has built a highly experienced cancer drug
development organization committed to advancing voreloxin in multiple
indications to improve the lives of people with cancer. For additional
information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com. 

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc. 

    Investor Contact:                           Media Contact:
    Sunesis Pharmaceuticals, Inc.               Sunesis Pharmaceuticals, Inc.
    Eric Bjerkholt                              Dan Weinseimer
    650-266-3717                                650-266-3739




SOURCE  Sunesis Pharmaceuticals, Inc.

Investors, Eric Bjerkholt, +1-650-266-3717, or Media, Dan Weinseimer,
+1-650-266-3739, both of Sunesis Pharmaceuticals, Inc.
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.